Tudor Investment Corp ET AL bought a new position in shares of Loxo Oncology, Inc. (NASDAQ:LOXO) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,442 shares of the biopharmaceutical company’s stock, valued at approximately $837,000.

Several other large investors also recently modified their holdings of LOXO. FMR LLC boosted its position in shares of Loxo Oncology by 20.6% during the first quarter. FMR LLC now owns 3,922,013 shares of the biopharmaceutical company’s stock worth $165,039,000 after acquiring an additional 670,306 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Loxo Oncology by 34.4% during the first quarter. Wellington Management Group LLP now owns 2,437,872 shares of the biopharmaceutical company’s stock worth $102,587,000 after acquiring an additional 623,730 shares during the last quarter. Alliancebernstein L.P. boosted its position in shares of Loxo Oncology by 6,330.9% during the first quarter. Alliancebernstein L.P. now owns 623,802 shares of the biopharmaceutical company’s stock worth $26,250,000 after acquiring an additional 614,102 shares during the last quarter. Marshall Wace North America L.P. bought a new position in shares of Loxo Oncology during the second quarter worth $33,347,000. Finally, State Street Corp boosted its position in shares of Loxo Oncology by 155.2% during the first quarter. State Street Corp now owns 547,017 shares of the biopharmaceutical company’s stock worth $23,019,000 after acquiring an additional 332,696 shares during the last quarter.

A number of equities analysts recently weighed in on the stock. BidaskClub lowered shares of Loxo Oncology from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. BTIG Research restated a “buy” rating and set a $75.00 target price on shares of Loxo Oncology in a research report on Thursday, August 3rd. Zacks Investment Research lowered shares of Loxo Oncology from a “buy” rating to a “hold” rating in a research report on Saturday, August 12th. Stifel Nicolaus restated a “buy” rating and set a $94.00 target price (up previously from $71.00) on shares of Loxo Oncology in a research report on Thursday, August 10th. Finally, Cowen and Company restated a “buy” rating on shares of Loxo Oncology in a research report on Thursday, September 28th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Loxo Oncology presently has an average rating of “Buy” and an average target price of $74.59.

COPYRIGHT VIOLATION NOTICE: “Tudor Investment Corp ET AL Invests $837,000 in Loxo Oncology, Inc. (LOXO)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/06/tudor-investment-corp-et-al-invests-837000-in-loxo-oncology-inc-loxo.html.

Loxo Oncology, Inc. (NASDAQ LOXO) opened at 88.15 on Friday. The company’s market cap is $2.63 billion. The firm’s 50-day moving average is $82.45 and its 200 day moving average is $65.62. Loxo Oncology, Inc. has a 52-week low of $17.14 and a 52-week high of $95.92.

Loxo Oncology (NASDAQ:LOXO) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.99) by ($0.15). During the same period last year, the firm earned ($0.77) EPS. On average, equities research analysts predict that Loxo Oncology, Inc. will post ($4.49) EPS for the current fiscal year.

In other news, insider Naarden Jacob Van sold 3,082 shares of the company’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $73.57, for a total transaction of $226,742.74. Following the completion of the sale, the insider now owns 1,541 shares of the company’s stock, valued at $113,371.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Joshua H. Bilenker sold 7,500 shares of the company’s stock in a transaction on Monday, September 18th. The stock was sold at an average price of $89.25, for a total transaction of $669,375.00. Following the sale, the chief executive officer now directly owns 196,207 shares of the company’s stock, valued at approximately $17,511,474.75. The disclosure for this sale can be found here. Insiders have sold 84,896 shares of company stock valued at $6,865,562 in the last ninety days. Insiders own 44.40% of the company’s stock.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Stock Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related stocks with our FREE daily email newsletter.